According to the most recent epidemiological data, the prevalence of hypertension ranged from about 25% in Chinese living either in the mainland or in Taiwan and Koreans, to approximately 40% in Mongolians. The control rate of hypertension was about 35% in Koreans and Japanese, 24%
in Mongolians, and less than 10% in Chinese. Four placebo-controlled trials in China unequivocally proved that antihypertensive therapy may prevent stroke and other cardiovascular complications in hypertension or patients with a history of stroke or transient ischemic attack. Four actively-controlled
trials in Japan did not show significant difference between various classes or combinations of antihypertensive drugs. Two trials that compared intensive with less intensive blood pressure control in elderly Japanese hypertensive patients did not show further benefit of controlling systolic
blood pressure to a level below 140 mmHg in comparison with blood pressure control to a level of 140 mmHg or above. These trials that compared various classes of antihypertensive drugs or intensive with less intensive blood pressure control often had small sample size and hence inadequate
power to detect modest or moderate benefit. There is still a need for high quality outcome trial data in East Asians.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 2016-09-01
More about this publication?
Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. Cardiovascular Innovations and Applications is the official journal of the Great Wall International Congress of Cardiology (GW-ICC). It aims to continue the work of the GW-ICC by providing a global scientific communication platform for cardiologists that bridges East and West.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites